Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis

Table 2 Meta-analysis of common adverse events with anti-PD-1/PD-L1 antibody therapy

Common AE	Any grade (%)	95%CI	Grade ≥ 3 (%)	95%CI
Fatigue	15.8	11.1-20.5	1.2	0.6-1.9
Infusion reaction	13.8	1.3-26.3	0.6	-0.2-1.4
Pruritus	13.1	9.8-16.4	NA	NA
Decreased appetite	9.6	5.7-13.5	0.9	0.2-1.6
Nausea	9.4	4.1-14.6	1.4	-2.5-5.4
Abdominal pain	9.3	-9.5-28.1	2.8	-3.4-9.0
Diarrhea	8.3	4.7-11.8	0.6	0.2-0.9
Pyrexia	8.0	1.3-14.6	NA	NA
Vomiting	7.8	0.1-15.4	NA	NA
Rash	7.3	5.2-9.4	0.9	-0.1-1.8
Arthralgia	6.2	3.4-9.0	NA	NA
Hypothyroidism	4.4	2.0-6.7	0.4	0-0.9
Elevated AST	4.1	2.1-6.2	1.5	-0.6-3.5
Asthenia	3.2	1.3-5.1	0.7	-0.2-1.6
Elevated ALT	2.7	1.2-4.1	0.9	-0.4-2.1
Pneumonitis	2.7	0-5.4	0.5	0-1.0
Elevated lipase	0.9	-0.4-2.2	0.7	-0.2-1.6
Colitis	0.8	0.2-1.4	0.4	0-0.8

AEs: Adverse events; CI: Confidence interval; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NA: Not available.